OncoMed Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018; Provides Earnings Guidance for the Year 2018
For the year 2018, the company's current cash is estimated to be sufficient to fund operations through at least the third quarter of 2019, without taking into account future potential milestone or opt-in payments from its partners. The company estimates 2018 operating cash burn to be approximately $55 million, before considering potential milestone or opt-in payments.